Currently Viewing:
Newsroom
Currently Reading
Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors
November 14, 2017 – AJMC Staff
Do Oral Parity Laws Reduce OOP Spending for Patients?
November 13, 2017 – Surabhi Dangi-Garimella, PhD
NEHI Recommends Implementing Value-Based Contracts With High-Cost Oncology Treatments
November 12, 2017 – Smita Jaggernauth, PharmD
MSK and PathoQuest Test Method to Detect Infection in Patients With Febrile Neutropenia
November 11, 2017 – AJMC Staff
This Week in Managed Care: November 10, 2017
November 10, 2017
Examining Top Reasons for Cancer-Related ED Visits
November 09, 2017 – Laura Joszt
Mutation May Be Associated With Resistance to NSCLC Immunotherapy
November 08, 2017 – Smita Jaggernauth, PharmD
Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC
November 07, 2017 – AJMC Staff
ASCO: Alcohol Linked to Several Types of Cancer
November 07, 2017 – Jaime Rosenberg

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

AJMC Staff
Cyclin-dependent kinase 4/6 inhibitors may have proven benefits for treating metastatic breast cancer, but the therapies are associated with hematological toxicities and febrile neutropenia.
Inhibition of cyclin-dependent kinase (CDK) 4/6 signaling has proven benefits for the majority of breast cancers that express the estrogen receptor or progesterone receptor. However, CDK 4/6 inhibitors are associated with hematological toxicities and febrile neutropenia (FN).

An abstract presented at the American Society of Clinical Oncology’s 2017 Palliative and Supportive Care in Oncology Symposium analyzed the risk of hematological toxicities and FN in patients with breast cancer using a literature search of MEDLINE and EMBASE databases and meeting abstracts.

Studies included were randomized controlled trials that mentioned anemia, thrombocytopenia, leukopenia, neutropenia, and neutropenic fever as adverse effects. In addition, studies had to compare CDK 4/6 inhibitors based on regimen and a control group with patients with hormone receptor–positive human epidermal growth factor receptor 2 (HER-2)–negative metastatic breast cancer.

The meta-analysis included 5 trials with 2671 patients total, with 4 of the studies in phase 3 and the other in phase 2.

The study arms used palbociclib-letrozole, palbociclib-fulvestrant, ribociclib-letrozole, and abemaciclib-fulvestrant, and the control arms used placebo with either letrozole or fulvestrant. The analysis found that the pooled risk of neutropenic fever was statistically significant at 4.26.

The relative risks of all-grade side effects were:
  • Anemia, 3.77
  • Thrombocytopenia, 9.69
  • Leukopenia, 11.68
  • Neutropenia, 14.09
The relative risks of high-grade adverse effects were:
  • Anemia, 2.55
  • Thrombocytopenia, 7.08
  • Leukopenia, 33.58
  • Neutropenia, 40.33
“CDK 4/6 inhibitors based regimen significantly contributed to all hematological toxicities as well as febrile neutropenia,” the authors concluded. “These toxicities affect patients’ quality of life, add financial burden and may lead to drug dosing inconsistencies.”

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up